Organisation paid for research Program year 2025 Source: CMS Open Payments

Avera Research Institute

Neither a doctor nor a teaching hospital

Research payments

$254,631

66 payments

Through program year 2025, Avera Research Institute is reported as receiving $254,631 in research payments, across 66 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $19,320 12
2024 Research $38,868 3
2023 Research $96,767 29
2022 Research $64,161 17
2021 Research $35,515 5

Breakdown

Who paid Research payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $234,055 63 payments
  2. Pfizer Inc. $18,625 2 payments
  3. Celgene Corporation $1,952 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. Phase 3B, Randomized, Observer-Blind. Multicenter Study to Assess the $85,151 21 payments
  2. A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarl $55,799 17 payments
  3. 1Nspire Study: Investigating 1L Maintenance Niraparib Safety and Patie $42,826 6 payments
  4. A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-033, An An $24,389 3 payments
  5. A Phase 23 Interventional Safety Pharmacokinetics and Efficacy Openlabel Multicenter Singlearm Study to Investigate Orally Administered Pf07321332 Nirmatrelvirritonavir in Nonhospitalized Symptomatic Pediatric Participants With Covid19 Who Are at Risk of Progression to Severe Disease $18,065 1 payment
  6. A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $14,927 9 payments
  7. Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $7,818 4 payments
  8. A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $3,145 3 payments
  9. A Phase-2 Study To Determine Efficacy and Safety o $1,952 1 payment
  10. A Phase 23 Interventional Safety Pharmacokinetics and Efficacy Openlabel Multicenter Singlearm Study to Investigate Orally Administered Pf07321332 Nirmatrelvirritonavir in Nonhospitalized Symptomatic Pediatric Participants With Covid19 Who Are at Risk of Progression to Severe Disease $560 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record